Company Overview
AbbVie Inc is a biotechnology company based in the United States and listed on the New York Stock Exchange. It develops and markets pharmaceutical products across immunology, oncology, neuroscience, and other therapeutic areas. With a market capitalization of about USD 411 billion, it is one of the largest players in its sector. The company’s portfolio combines established treatments with ongoing research programs aimed at sustaining long-term growth.
Analysis of recent data
FundamentalsAbbVie’s latest 10-K for the period ending December 31, 2025, reported USD figures with revenue of 61.16 billion and EBIT of 241 million. Revenue grew 8.6% year over year, while net income was not provided. Depreciation and amortization totaled 762 million, and the free-cash-flow proxy excluding working-capital changes was 965 million.
Profitability metrics show a 71.62% gross margin and a 24.65% operating margin, indicating strong cost control. However, the net margin of 6.91% highlights a gap between operating and bottom-line performance. The return on equity of 95.59% suggests high capital efficiency, though the absence of net income data limits clarity on earnings quality.
Total debt stood at 8.56 billion, while cash and capital expenditure data were not provided. The company’s beta of 0.33 indicates relatively low market volatility. Overall, AbbVie’s operating performance remains solid, but incomplete financial disclosures constrain a full assessment of profitability stability.
Valuation
DCF / MultiplesAt a share price of USD 232.35, the DCF fair-value range spans USD 162.56 (bear), USD 249.72 (base), and USD 362.47 (bull). The current valuation implies confidence in maintaining robust operating margins.
With a trailing P/E of 97.22 and an EV/EBITDA of 47.10, the market appears to price in sustained profitability and limited risk. The base-case fair value slightly above the current price suggests moderate upside potential if operating margins remain stable.
Conclusion
TakeawayAbbVie’s financial profile shows strong operating efficiency but incomplete earnings data. The market seems to expect continued margin strength. Investors may find the valuation reasonable given the company’s scale and stability. Patience could be rewarded if profitability steadies over time.